US Edition
News from TBNweekly
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top TBNweekly News
Tariffs · United StatesThe U.S. Trade Representative office on Friday said it had launched a new tariff investigation into China's "apparent failure" to comply with the "Phase One" trade deal signed with President Donald Trump in 2020 to end his first-term U.S.-China trade war.See the Story
US launches investigation into China's compliance with 2020 trade deal
64% Center coverage: 92 sources
New York City · New YorkNEW YORK, Oct. 24, 2025 /PRNewswire/ -- BBB National Programs' National Advertising Division today determined that AT&T Services, Inc. violated Section 2.1(I) of the National Advertising Division (NAD)/National Advertising Review Board (NARB) Procedures for the U.S. advertising industry's process of…See the Story
AT&T Violates BBB National Programs' National Advertising Division Procedures
65% Center coverage: 32 sources
Burlington, North Carolina · BurlingtonNipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score , which is based on 11 key systemic disease domains, at Week 24 versus…See the Story
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
65% Center coverage: 29 sources
